Beam Therapeutics BEAM Sales of and distributions from equity method investments

Sales of and distributions from equity method investments at other companies

Devon EnergyDVN

$9M0.0%

Hewlett Packard EnterpriseHPE

$0-100%

GE VernovaGEV

$44M-51.1%

Devon EnergyDVN

$9M0.0%

Williams CompaniesWMB

$40.25M—

MastercardMA

$45.25M-55.6%

Other financials

Income statement

See full

Revenue$31.7M+325%

Operating income-$107.2M+10.1%

Net income-$94.3M+12.9%

EPS (diluted)-$0.91+26.0%

Balance sheet

See full

Cash & equivalents$288.3M-45.4%

Total debt$250.8M+58.6%

Total equity$1.2B+3.1%

Total assets$1.5B+0.9%

Cash flow

See full

Operating cash flow-$128.5M-23.7%

CapEx$2.2M-27.2%

Free cash flow-$130.7M-22.2%

Valuation

See full

Market cap$3.42B+24.5%

Profitability

See full

Operating margin-226.6%-90.5pp

Net margin-742.7%—

FCF margin-234%-86.6pp

Returns & leverage

See full

Return on equity-47.1%—

Debt / equity0.2×+0.1×

Current ratio17×+8.2×

Where this comes from

Reported directly by Beam Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleOfEquityMethodInvestments.

The official record: Beam Therapeutics’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →

Ask your AI about Beam Therapeutics's sales of and distributions from equity method investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Beam Therapeutics's sales of and distributions from equity method investments?: Beam Therapeutics (BEAM) reported sales of and distributions from equity method investments of $63.79M in Q4 2025.